MedTrace Logo

An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®

NCT01046903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 503

Last updated 2012-02-27

Study results available
· View outcomes & findings →

Summary

The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Fragmin® (Dalteparin Sodium)

Administered per prescribing physician

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-02-28
Completion
2011-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046903 on ClinicalTrials.gov